Africa–Oxford–Harvard/Hopkins Cancer Research and Clinical trials Consortium (AFROX-H2 Clinical Trials Network)

Clicks: 1
ID: 311764
2022
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #610 of 631 articles by views in science and technology of advanced materials

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 631 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This chapter covers the AFROx-H2 Network, which includes cancer centers from different African countries with support from Oxford University and colleagues at Harvard and Johns Hopkins. A first AFROx-H2 clinical trial is in motion, with a focus on hypofractionated radiotherapy, and will be followed by trials using biomaterial drone technology developed at Harvard. This network is a great epitome of the win-win scientific initiative.
Reference Key
persistent_1771692106_6999e04a1d679 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors David Kerr, Twalib Ngoma, Wil Ngwa, Ahmed Elzawawy, Dennis Palmer, Francine Kouya, Paul Mobit, Verna Vanderpuye, N A Othieno-Abinya, Atara Ntekim, Paul Ruff
Journal science and technology of advanced materials
Year 2022
DOI
10.1088/978-0-7503-3075-6ch11
URL
https://iopscience.iop.org/book/edit/978-0-7503-3075-6/chapter/bk978-0-7503-3075-6ch11.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.